针对异常性肺纤维化症的药理疗法的网络元分析:评估对肺功能的影响
Yajie Yin1, Xinhui Wu1, Zhihao Liu1
1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in pharmacology
|March 11, 2026
概括
这次审查分析了162项针对异常性肺纤维化 (IPF) 治疗的试验. 涅拉多米拉斯提升了强迫性生命能力 (FVC),而N-乙半氨酸 (NAC) 与罗西胺素 (RXM) 增强了生命能力 (VC) 和FEV1/FVC.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 异常性肺纤维化 (IPF) 是一种进展性肺病,肺功能下降.
- 目前的治疗方法旨在减缓IPF的进展,但它们的有效性需要系统评估.
- 了解药物对肺功能指标的影响对于IPF管理至关重要.
研究的目的:
- 系统地审查和进行随机对照试验的网络元分析.
- 评估药理治疗对IPF患者肺功能功能的有效性.
- 为了比较不同药物在改善关键肺功能参数方面的疗效.
主要方法:
- 在八个数据库中系统搜索相关的随机对照试验.
- 使用Cochrane手册工具进行偏见风险评估.
- 使用Stata 19.0和R 4.5.1软件进行的网络元分析;协议注册在PROSPERO.
主要成果:
- 包括162项涉及16525名IPF患者的研究.
- 在改善强迫生命能力 (FVC) 方面,Nerandomilast是最有效的.
- N-乙半氨酸 (NAC) + 红色素 (RXM) 改善了生命能力 (VC) 和FEV1/FVC;安布罗克索尔改善了肺部总容量 (TLC);塔利多米德改善了肺部对一氧化碳 (DLCO) 的扩散能力.
结论:
- 不同的药物针对IPF的不同肺功能参数.
- 涅兰多米拉斯特,NAC+RXM,安布罗克索和塔利多米德在改善特定的肺功能方面表现有前途.
- 需要更高质量的研究来验证研究结果并评估新型IPF疗法的长期有效性.
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
573
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
573
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
274
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
274
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.3K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.3K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320